We previously modulated, by conjugating a single cholesterol, plasma protein binding and liver cell uptake of a phosphorothioate oligodeoxynucleotide (PS-ODN). In this study, we investigated the biological fate of a PS-ODN, denoted ISIS-9389 (3Ј,5Ј-bis-cholesteryl-conjugated ISIS 3082), provided with two cholesteryl moieties. After intravenous injection of into rats, [ 3 H]ISIS-9389 was cleared from plasma with a half-life of 23.6 Ϯ 0.3 min. After 90 min (approximately 95% cleared), the liver contained 83.0 Ϯ 0.8% of the dose. Spleen and bone (marrow), which constitute with the liver the reticuloendothelial system, contained 3.1 Ϯ 0.3 and 4.3 Ϯ 0.2%, respectively. All other tissues accumulated together Ͻ5% of the dose. The hepatic uptake of [ 3 H]ISIS-9389 occurred mainly by endothelial cells (51.9 Ϯ 6.4% of the liver uptake). Parenchymal and Kupffer cells were responsible for 24.9 Ϯ 7.7 and 23.3 Ϯ 2.5%, respectively. Preinjected polyinosinic acid and polyadenylic acid reduced hepatic uptake, albeit the latter was less effective. This finding suggests implication of (multiple) scavenger receptors in liver uptake of ISIS-9389. The interaction of ISIS-9389 with plasma proteins, analyzed by size exclusion chromatography, differs from that of unconjugated PS-ODN and PS-ODN with a single cholesterol. Plasma-incubated ISIS-9389 was mainly recovered as a high molecular weight complex. In conclusion, conjugation of PS-ODNs with two cholesteryl moieties results in almost quantitative uptake by the liver. The liver targeting exceeds the already impressive gain in liver uptake achieved by conjugation of a single cholesterol, and is expected to increase the therapeutic activity against liver-associated targets and reduce side effects in nonhepatic tissues.
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Antisense oligonucleotides, designed to sequence specifically down-regulate the expression of target genes, have great potential as a research tool and as therapeutic agents (Szymkowski, 1996; Juliano et. al., 1999; Akhtar et al., 2000) . A multitude of nuclease-resistant oligonucleotide analogs has been developed, of which the phosphorothioate analog is the most widely applied. Antisense phosphorothioate oligodeoxynucleotides (PS-ODNs) have been tested in a variety of in vitro and in vivo systems and were shown to be potent inhibitors of the expression of their target genes (Szymkowski, 1996; Juliano et al., 1999; Akhtar et al., 2000) . Several have entered clinical trials, and a cytomegalovirus-specific PS-ODN (Vitravene) is approved for marketing (Akhtar et al., 2000) .
In spite of many successful applications, the issue of effective cellular delivery of PS-ODNs remains to be resolved. Being large polyanions, PS-ODNs do not readily penetrate cell membranes. Various delivery strategies have been developed to increase the cellular uptake of PS-ODNs. Complexation of PS-ODNs with cationic lipids is at present commonly applied to facilitate their uptake by cells in culture, but it is not very suited for use in vivo (Juliano et al., 1999; Akhtar et al., 2000) . An approach that was found to be effective, both in vivo and in vitro, is conjugation of PS-ODNs with cholesterol. It has been demonstrated in several cellular and animal models that cholesteryl-conjugated PS-ODNs display a higher antisense activity than their unconjugated counterparts (Desjardins et al., 1995; Alahari et al., 1996; Epa et al., 1998; Okamoto and Nakano, 1999) . Furthermore, it has recently been claimed that conjugation with cholesterol improves the oral bioavailability of PSODNs (Okamoto and Nakano, 1999) . The improved efficacy of the cholesteryl-conjugated PS-ODNs may be explained by a higher cellular uptake, because it has been found in several studies that conjugation with cholesterol enhances the association of PS-ODNs with cells in culture (Temsamani et al., 1994; Alahari et al., 1996; Epa et al., 1998) . Furthermore, we showed recently that the attachment of a single cholesterol at the 3Ј end of a PS-ODNs also affects the in vivo fate of the oligonucleotide. The cholesteryl-conjugated PS-ODN was found to display altered plasma protein binding and higher liver uptake . In the present study, we investigate the disposition of a PS-ODN that is conjugated with cholesterol at both the 3Ј and 5Ј ends. It is shown that conjugation of a second cholesterol, in addition to a single cholesterol, markedly alters the plasma protein binding and disposition of the PS-ODN.
Materials and Methods
Reagents. Polyinosinic acid (5Ј), polyadenylic acid (5Ј), and rat serum albumin were from Sigma-Aldrich (St. Louis, MO). Emulsifier Safe and Hionic Fluor scintillation cocktails and Soluene-350 were from Packard Instrument Company, Inc. (Downers Grove, IL). Na 125 I (carrier-free) was from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK). Proteinase K was purchased from Roche Applied Science (Mannheim, Germany). All other reagents were of analytical grade.
Oligonucleotide Synthesis and Purification. PS-ODNs, specific for murine intercellular adhesion molecule-1 (ICAM-1), were used. ISIS-3082 (sequence 5Ј-TGC ATC CCC CAG GCC ACC AT-3Ј) and ISIS-9388 (same sequence as ISIS-3082 with a 3Ј-cholesterolmodified uridine as 3Ј-end base instead of thymidine) were synthesized and 3 H labeled as described previously (Stepkowski et al., 1994; Bijsterbosch et al., 1997 Bijsterbosch et al., , 2000 . ISIS-9389 was synthesized as ISIS-9388. The synthesis was carried out using the phosphoramidite that was derived from condensing 5Ј-DMT-2Ј-O-(6-aminohexyl)-thymidine with cholesteryl chloroformate and subsequent phosphitylation (Manoharan et al., 1995) . To allow monitoring of its biological fate, ISIS-9389 was radiolabeled with 3 H by heat-catalyzed exchange at the C8 positions of the purine nucleotides as described previously (Graham et al., 1993) . [
3 H]ISIS-9389 was purified by reversed phase high-performance liquid chromatography, using a C 4 column (5 m, 300 Å, 300 ϫ 3.9 mm; Waters, Milford, MA), at a flow rate of 1 ml/min using the following mobile phases: A, 50 mM triethyl ammonium acetate, pH 7.0; and B, acetonitrile. After injection of the samples (0.5 ml), the column was eluted for 5 min with 10% B, followed by a gradient of 10 to 90% B (25 min). Subsequently, the column was eluted for 10 min with 90% B. The retention time of ISIS-9389 under these conditions was approximately 28 min (ISIS-3082 and ISIS-9388, 13 and 25 min, respectively). The radiolabeled oligonucleotide was precipitated as sodium salt by adding 10 volumes of 3% (w/v) NaClO 4 in acetone as described previously (Rump et al., 1998) . The specific radioactivity of [ 3 H]ISIS-9389 was approximately 50 ϫ 10 6 dpm/mg, and the radiochemical purity Ͼ98%. Isolation and Radioiodination of Rat Lipoproteins. Rat lowdensity lipoprotein (LDL; density 1.024 -1.063 g/ml) and rat highdensity lipoprotein (HDL; density 1.063-1.210 g/ml) were isolated by density gradient centrifugation and radioiodinated with carrier-free 125 I as described previously . Less than 2% of the radioactivity in the labeled protein preparations was trichloroacetic acid-soluble.
Determination of Stability of ISIS-9389 in Rat Serum and Plasma.[
3 H]ISIS-9389 was incubated at 37°C at a concentration of 20 g/ml with rat serum or EDTA-plasma (4 mM EDTA). After 90 min, aliquots of 200 l of the incubation mixtures were mixed with an equal volume of extraction buffer (25 mM Tris-HCl buffer, pH 8.0, containing 25 mM EDTA, 100 mM NaCl, 0.5% Nonidet P-40, and 1 mg/ml proteinase K), and incubated for a further 2 h at 56°C. Subsequently, the samples were mixed with 400 l of phenol/isoamyl alcohol/chloroform (25:1:24, by volume). After shaking for 10 min, the phases were separated by centrifugation. The organic phase was washed four times with 400 l of water. The aqueous phases were combined (total extraction efficiency approximately 40%), and dried in a Speed-Vac concentrator. The residues were dissolved in water, and 30 g of unlabeled ISIS-9389 was added as marker (final volume 600 l). An aliquot of 500 l was subjected to reversed phase highperformance liquid chromatography as described above. Fractions of 1 ml were collected and assayed for radioactivity. It was found that after 90 min of incubation of [ 3 H]ISIS-9389 with rat serum or plasma, Ͼ95% of the radioactivity eluted at the position of the unlabeled ISIS-9389 marker. Because the retention of ISIS-9389 depends on the presence of cholesterol, this indicates that the radiolabeled oligonucleotide still contains both cholesterol moieties, implicating that it was fully intact.
Determination of Plasma Clearance and Tissue Distribution. Male Wistar rats, weighing between 200 and 350 g, were used. The animals were anesthetized by intraperitoneal injection of sodium pentobarbital (60 mg/kg of body weight), and the abdomen was opened. Radiolabeled oligonucleotide, dissolved in phosphate-buffered saline (10 mM sodium phosphate buffer, pH 7.4, containing 0.15 M NaCl), was injected via the vena penis (2 ml/kg of body weight). At the indicated times, blood samples of 0.2 to 0.3 ml were taken from the inferior vena cava and collected in heparinized tubes. The samples were centrifuged for 2 min at 16,000g, and the plasma assayed for radioactivity. The total amount of radioactivity in plasma was calculated using the equation plasma volume (ml) ϭ [0.0219 ϫ body weight (g)] ϩ 2.66 (Bijsterbosch et al., 1989) . At the indicated times, liver lobules were tied off and excised, and at the end of the experiment the remainder of the liver was removed. The amount of liver tissue tied off successively did not exceed 15% of the total liver mass. The amount of radioactivity in the liver at each time point was calculated from the radioactivities and weights of the liver samples. Uptake by extrahepatic tissues was determined by removing the tissues at the end of the experiment and counting of radioactivity. Radioactivity in tissues was corrected for radioactivity in plasma present in the tissue at the time of sampling (Bijsterbosch et al., 1989) .
Pharmacokinetic Analysis. The plasma clearance of intravenously injected radiolabeled oligonucleotide was analyzed by a nonlinear regression program (GraphPad; ISI Software, San Diego, CA). The data were fit by a two-compartment model. The distribution volume (V dis ) was calculated by extrapolation of the elimination curve to time 0. The half-life of elimination was calculated from the elimination rate constant (k e ) using the formula T 1/2 ϭ 0.693/k e . The total plasma clearance (CL) was calculated using the formula CL ϭ V dis ϫ k e .
Determination of Distribution over Liver Cell Types. Rats were anesthetized and injected with radiolabeled oligonucleotides as described above. The liver was perfused at 60 min after injection, and parenchymal, Kupffer, and endothelial cells were isolated from the liver as described in detail previously (Nagelkerke et al., 1983) . The cell fractions were assayed for radioactivity and protein. Shortly before separation of the cells, a liver lobule was tied off and excised to determine the total liver uptake. The contributions of the various cell types to the total liver uptake was calculated from the uptake per milligram of cell protein and the contribution of each cell type to the total liver protein (Nagelkerke et al., 1983) . As found with other ligands (Nagelkerke et al., 1983; Bijsterbosch et al., 1989) , no significant amounts of radioactivity were lost from the cells during the isolation procedure. This was checked in each experiment by comparing the calculated liver uptake (i.e., the summation of the contributions of the various cell types) with the value actually measured in the liver lobule. The percentage of the dose taken up by each cell type was calculated from the contribution of the cells to the total liver uptake and the contribution of the liver to the clearance of ISIS-9389. The overall intracellular concentrations were calculated from the molecular weight of the oligonucleotide, liver weight (4.3 Ϯ 0.1% of body weight, mean Ϯ S.E.M. of 10 determinations), liver density (1.07 mg/ml; Blouin et al., 1977) , and the volumes of the different cellular compartments in the liver (Blouin et al., 1977 were also incubated with rat plasma. After 30 min, aliquots of the incubation mixtures were injected onto a Superose 6 Precision column (3.2 ϫ 300 mm), equipped with a 50-l sample loop (Amersham Biosciences AB, Uppsala, Sweden). The column was eluted with phosphatebuffered saline at a flow rate of 50 l/min. Fractions of 100 l were collected and assayed for radioactivity. To determine association with lipoproteins, [
3 H]ISIS-9389 was incubated at 37°C with rat 125 I-LDL or rat 125 I-HDL, dissolved in phosphate-buffered saline. The incubation mixtures were analyzed as described above.
Determination of Proteins. Protein concentrations in cell suspensions and preparations of LDL and HDL were determined by the method of Lowry et al. (1951) , with a bovine serum albumin standard.
Determination of Radioactivity. Samples containing 3 H were counted in a Packard Tri-Carb 1500 liquid scintillation counter. Liquid samples were counted without further processing by liquid scintillation spectroscopy, using Emulsifier Safe or Hionic Fluor scintillation cocktails. Tissue samples were processed using a Packard 306 sample oxidizer. Some tissues (e.g., bone) were dissolved in 10 M NaOH at 95°C before counting. In samples containing both 125 I and 3 H, the 125 I radioactivity was counted in a Packard Auto-Gamma 5000 counter. The 3 H radioactivity was subsequently measured as described above and corrected for the contribution of 125 I radioactivity.
Results
Plasma Clearance and Tissue Uptake of ISIS-9389. A 3Ј,5Ј-bis-cholesteryl-conjugated PS-ODN specific for murine ICAM-I, denoted ISIS-9389, was used as test compound (Table 1). The unconjugated and 3Ј-cholesteryl-conjugated counterparts (ISIS-3082 and ISIS-9388, respectively) were used for comparison (Bijsterbosch et al., 1997 . The disposition of ISIS-9389 was studied after an intravenous bolus injection of the radiolabeled oligonucleotide into rats. The dose, 1 mg/kg of body weight, was in the range of doses of ICAM-1-directed antisense oligonucleotides that have been found to be effective in preclinical models and in patients (Stepkowski et al., 1994 (Stepkowski et al., , 1998 Bennett et al., 1997; Yacyshyn et al., 1998) . Figure 1 shows the plasma clearance of radioactivity after injection of [ 3 H]ISIS-9389. After an initial rapid distribution phase, radioactivity was cleared from the circulation with a half-life of 23.6 Ϯ 0.3 min. The plasma clearance of ISIS-9389 was followed for 90 min. In vitro incubation studies with rat plasma and serum indicate that ISIS-9389 remains for Ͼ95% intact during this time period. In Table 2 , the pharmacokinetic parameters of ISIS-9389 are compared with those of ISIS-3082 and ISIS-9388. The distribution volumes of the three oligonucleotides were not significantly different. ISIS-9389 was cleared from the circulation at approximately the same rate as the parent compound ISIS-3082, but more rapidly than the mono-cholesteryl derivative ISIS-9388.
At 90 min after injection, when approximately 95% of the injected dose of [ 3 H]ISIS-9389 had been cleared from the circulation, the distribution of the radioactivity over the body was determined. The results are shown in Table 3 . The most striking finding is the high amount of radioactivity in the liver: 83.0 Ϯ 0.8% of the dose, which corresponds to 87.8 Ϯ 0.8% of the cleared amount. The only other tissues that contained significant amounts of radioactivity were the spleen and the bone (marrow). Liver, spleen, and bone (marrow) together account for Ͼ95% of the clearance of ISIS-9389. Even bulky tissues such as skin and muscle contained Ͻ1% of the dose. Kidneys, which play a prominent role in the disposition of unconjugated PS-ODNs (Bijsterbosch et al., 1997) , accumulated only a minor amount of ISIS-9389 (Ͻ0.5% of the dose). The specific uptake of liver, spleen, and bone marrow (expressed as relative specific radioactivity) is at least 1 order of magnitude higher than that of any other tissue. Figure 2 compares the tissue distribution of ISIS-9389 with those of ISIS-3082 and ISIS-9388. The liver is the most important tissue in the uptake of all three oligonucleotides, but conjugation with cholesterol enhances the liver uptake. ISIS-3082 is taken up for about 40% by the liver, whereas the hepatic uptake of the 3Ј-cholesterol-modified derivative ISIS-9388 is approximately 70%. Conjugation of a second cholesterol, yielding ISIS-9389, results in almost exclusive elimination by the liver.
Cellular Distribution of ISIS-9389 in Liver. The liver contains several actively endocytosing cell types (Ashwell and Harford, 1982; Smedsrod et al., 1994) . To identify the cell type(s) responsible for the hepatic uptake of ISIS-9389, rats were injected with the radiolabeled oligonucleotide. Paren- Cholesterol-5Ј-TGCATCCCCCAGGCCACCAT-3Ј-Cholesterol chymal, endothelial, and Kupffer cells were isolated from the liver 60 min later, and assayed for radioactivity. The cell isolation procedure was performed at a low temperature (8°C) to prevent processing of internalized oligonucleotide. The results are shown in Table 4 . Endothelial cells were the major site of uptake in the liver (51.9 Ϯ 6.4% of the liver uptake), whereas Kupffer and parenchymal accounted each for approximately 25% of the liver uptake. When all injected oligonucleotide is cleared from the circulation, 87.7 Ϯ 0.8% of the injected dose is taken up by the liver. It can thus be calculated that endothelial, Kupffer, and parenchymal cells accumulate 45.5 Ϯ 5.6, 20.4 Ϯ 2.2, and 21.8 Ϯ 6.7% of the injected amount of oligonucleotide, respectively. Intracellular concentrations of ISIS-9388 in endothelial, Kupffer, and parenchymal cells can be calculated from these data and from the sizes of the three different cellular compartments. Parenchymal and Kupffer cells contribute to a similar extent to the hepatic uptake of ISIS-9389. However, parenchymal cells constitute Ͼ90% of the cellular mass and Kupffer cells only 2.5%. The concentration of ISIS-9389 in Kupffer cells is therefore much higher than in parenchymal cells (51.5 Ϯ 5.5 versus 1.5 Ϯ 0.5 M). However, the highest concentration of ISIS-9389 is in endothelial cells (86.1 Ϯ 10.6 M). Figure 3 compares the accumulation of ISIS-9389 in the different liver cell types with those of ISIS-3082 and ISIS-9388. Conjugation of the PS-ODN with cholesterol results in higher uptake by all three liver cell types under investigation, but uptake by nonparenchymal cells, in particular Kupffer cells, is more increased than uptake by the parenchymal cells.
Implication of Scavenger Receptors in Liver Uptake of ISIS-9389. We demonstrated previously the role of scavenger receptors in the hepatic uptake of ISIS-3082 and ISIS-9388 (Bijsterbosch et al., 1997 . Endothelial liver cells, and to a lesser extent Kupffer cells, express the type AI/II scavenger receptor (SR-AI/AII), which binds and internalizes a variety of polyanionic ligands (Nagelkerke et al., 1983; Krieger and Herz, 1994; van Berkel et al., 1998) . Interaction of ligands with SR-AI/AII can be effectively inhibited by polyinosinic acid (poly-I), whereas polyadenylic acid (poly-A) is a poor inhibitor (Pierson et al., 1993) . To study the possible role of SR-AI/II in the liver uptake of ISIS-9389, rats were preinjected with poly-I or poly-A shortly before injection of [ 3 H]ISIS-9389. The uptake of ISIS-9389 by the liver was substantially inhibited by poly-I (Fig. 4) . Poly-A also inhibited the hepatic uptake of ISIS-9388, but it was less effective than poly-I. These findings suggest that scavenger receptors play a major role in the hepatic uptake of ISIS-9388. The inhibition of uptake of the oligonucleotide by both poly-I and poly-A suggests that, in addition to SR-AI/II, alternative scavenger receptor systems are implicated.
Association of ISIS-9389 with Plasma Proteins. PSODNs bind to plasma proteins, which is likely to affect their disposition (Cossum et al., 1993; Srinivasan et al., 1995; Nolting et al., 1997) . We found that the association of cholesteryl-derivatized ISIS-9388 with plasma proteins differs from that of nonconjugated ISIS-3082 (Bijsterbosch et al., 3 H]ISIS-9389 was incubated with rat plasma (at 20 g/ml; the concentration immediately after injection). After 30 min, the mixture was subjected to size exclusion chromatography. For comparison, [
3 H]ISIS-3082 and [ 3 H]ISIS-9388 were also incubated with plasma and subjected to size exclusion chromatography. Figure 5 shows 3 H]ISIS-9389 was predominantly recovered in fractions eluting at 0.90 to 1.50 ml. These fractions contain lipoproteins and high molecular weight plasma proteins (molecular weights Ͼ300,000), such as ␣ 1 -macroglobulin . Only a small proportion (15-20%) was recovered in fractions eluting at 1.50 to 1.90 ml, which contain the bulk of the plasma proteins.
It has been shown in several studies that conjugation with cholesterol induces association of oligonucleotides with lipoproteins (Krieg et al., 1993; Rump et al., 1998; Bijsterbosch et al., 2000) . ISIS-9389 carries two cholesterol residues, which may lead to cross-linking of lipoprotein particles, when ISIS-9389 is present in plasma. To assess the interaction of ISIS-9389 with LDL and HDL, [
3 H]ISIS-9389 (20 g/ml) was incubated with radioiodinated LDL and HDL (0.2 and 1.0 mg/ml, respectively; the concentrations in rat plasma). The incubation mixtures were analyzed by size exclusion chromatography. Figure 6 shows that ISIS-9389 associates readily and quantitatively with LDL and HDL. The complexes of b Contribution of each cell type to the total liver uptake was calculated from the uptake per milligram of cell protein and the contribution of each cell type to the total liver protein (Nagelkerke et al., 1983) .
c Percentage of the administered dose taken up by each cell type (when all oligonucleotide is cleared) was calculated from the contribution of the cells to the total liver uptake and the contribution of the liver to the clearance of ISIS-9389 (87.7 Ϯ 0.8%).
d Total cellular loads (intracellular concentrations reached when all oligonucleotide is cleared) were calculated from the sizes of the different cellular compartments (details under Materials and Methods).
e Values are means Ϯ S.E.M. of four rats. , all at a dose of 1 mg/kg of body weight. After 60 min, parenchymal, endothelial, and Kupffer cells were isolated, and the association of radioactivity to each cell type was determined. The contribution of each cell type to the total liver uptake was calculated from the uptake per milligram of cell protein and the contribution of each cell type to the total liver protein (Nagelkerke et al., 1983) . The percentage of the administered dose taken up by each cell type (when all oligonucleotide is cleared) was calculated from the contribution of each cell type to the total liver uptake and the contribution of the liver to the clearance (41.4 Ϯ 1.4, 71.7 Ϯ 3.7, and 87.7 Ϯ 0.8% of the dose for ISIS-3082, ISIS-9388, and ISIS-9389, respectively). Values are means Ϯ S.E.M. of three to four rats. 3 H]ISIS-9389 at a dose of 1 mg/kg of body weight. Shortly (1 min) before the injection of the labeled ligand, the animals received 10 mg/kg polyinosinic acid (poly-I; F), 10 mg/kg polyadenylic acid (poly-A; E), or an equal volume of saline solvent (f; 2 ml/kg). At the indicated times, the amounts of radioactivity in the liver were determined. Values are means Ϯ S.E.M. of three to four rats. 
Selective Liver Uptake of bis-Cholesteryl

Discussion
In the present study, we found that the conjugation of two cholesteryl residues to a PS-ODN results in almost complete hepatic uptake of the oligonucleotide in the rat. Spleen and bone marrow, which constitute together with the liver the reticuloendothelial system, also actively accumulated the bis-cholesteryl-conjugated oligonucleotide. Liver, spleen, and bone marrow together accounted for Ͼ95% of the clearance. Kidneys, which play a major role in the disposition of unconjugated oligonucleotide (Bijsterbosch et al., 1997) , accumulated only a minor amount (Ͻ0.5% of the dose). It was found previously that conjugation of a single cholesterol at either end substantially increases the hepatic uptake of PS-ODNs (Crooke et al., 1996; Bijsterbosch et al., 2000) . We show herein that an even higher targeting to the liver can be achieved by conjugation of cholesterol to both ends.
Within the liver, endothelial cells contribute most (51.9 Ϯ 6.4%) to the uptake, whereas parenchymal and Kupffer cells accounted each for approximately 25% of the hepatic uptake. . The present data indicate that derivatization with a second cholesterol does not appreciably affect the intrahepatic distribution, because the distribution of ISIS-9389 over liver cell types is very similar to that of ISIS-9388.
We reported previously that scavenger receptors are implicated in the hepatic uptake of ISIS-3082 and ISIS-9388 (Bijsterbosch et al., 1997, 2000) . The term scavenger receptor is used for a variety of proteins that bind negatively charged ligands. Six classes of receptors are distinguished within the scavenger receptor family (Krieger, 1997; Greaves et al., 1998; Terpstra et al., 2000) . Class A receptors were the first to be identified and cloned and are the best characterized. Endothelial cells, and to a lesser extent Kupffer cells, abundantly express the SR-AI/AII. These receptors bind a wide variety of polyanionic ligands, including modified (lipo)proteins, polynucleotides, and polysaccharides (Krieger and Herz, 1994) . The three-dimensional structure of polynucleotides is an important determinant for their affinity for SR-AI/AII (Pearson et al., 1993; van Berkel et al., 1998) . Poly-I binds tightly to the receptors, whereas poly-A is poorly bound. The different abilities of poly-I and poly-A to inhibit the interaction of ligands with SR-AI/AII were used to examine the role of SR-AI/AII in liver uptake. Poly-I and poly-A both inhibited the liver uptake of ISIS-9389, albeit that the (f) were incubated at 37°C with rat plasma, at a concentration of 20 g/ml. After 30 min, aliquots of the incubation mixtures were subjected to size exclusion chromatography on a Superose 6 column. Fractions of 0.1 ml were collected and assayed for radioactivity. The results are expressed as percentages of the recovered amounts (recoveries Ͼ95%). The void volume of the column, and the elution volumes of LDL, HDL, serum albumin (SA), and free oligodeoxynucleotide (ODN) are indicated by arrows. latter was less effective. This indicates that at least part of the hepatic uptake occurs via scavenger receptors that are sensitive to poly-A inhibition. However, the molecular nature of these receptors remains to be established. Several candidate receptors have been described. Endothelial cells of various species have been found to express scavenger receptors that are different from the SR-AI/AII (Krieger, 1997; van Berkel et al., 1998; Greaves et al., 1998; Terpstra et al., 2000) . Furthermore, it was found that Kupffer cells express scavenger receptors that recognize oxidized LDL and are likely related to macrosialin and CD68 (van Velzen et al., 1997) .
The different biological behavior of ISIS-9389, compared with ISIS-3082 and ISIS-9388, may be due to the different binding of the oligonucleotides to plasma proteins. Analysis by size exclusion chromatography indicates that the binding of ISIS-9389 to plasma proteins is different from that of ISIS-3082 and ISIS-9388. ISIS-9389 elutes predominantly with high molecular weight proteins (molecular weights Ͼ300,000). The plasma components that bind ISIS-9389 remain to be identified. ISIS-9389 binds to LDL and HDL, when incubated with these lipoproteins alone. However, it is not likely that ISIS-9389 is also associated with lipoproteins in blood plasma. HDL is the major lipoprotein in rat plasma, but we detected no appreciable binding of ISIS-9389 to HDL after incubation with rat plasma. There are also no indications that the bis-cholesteryl-derivatized ISIS-9389 induces cross-linkage of LDL and HDL. Analysis by size exclusion chromatography of complexes of ISIS-9389 with both lipoproteins showed that the complexes eluted at the same position as native LDL and HDL. It is, however, possible that ISIS-9389 induces multimer formation of other, as yet unidentified plasma components. Further experiments need to be performed to identify the plasma proteins involved in the binding of ISIS-9389.
Our results indicate that bis-cholesteryl conjugation has implications for the therapeutic application of PS-ODNs. Bischolesteryl-conjugated PS-ODNs are almost exclusively taken up by liver, spleen, and bone marrow. In the liver, by far the highest concentrations were found in the cells of the endothelial lining: Kupffer and endothelial cells. We did not examine the cellular localization of ISIS-9389 in spleen and bone marrow, but it is likely that ISIS-9389 accumulates in these organs also in reticuloendothelial cells. The selective accumulation of bis-cholesteryl-conjugated oligonucleotide in reticuloendothelial cells is beneficial when genes expressed in these cells are targeted. For example, ICAM-1 is up-regulated on Kupffer cells and liver endothelial cells under inflammatory conditions, which results in the harmful infiltration of neutrophils into the liver (van Oosten et al., 1995; Jaeschke et al., 1996) . It has been shown that systemically administered unconjugated PS-ODNs specific for ICAM-1 reduce the adherence of neutrophils to the cells of the endothelial lining in the liver, and consequently exert a therapeutic effect (Wong et al., 1997) . A higher cellular accumulation of these oligonucleotides, achieved by cholesterol conjugation, is expected to result in an improved therapeutic effect. Moreover, the reduced uptake by nontarget tissues, in particular kidneys, will reduce side effects. After administration of unconjugated PS-ODNs, kidneys contain the highest concentrations of PS-ODNs, which results in several morphological changes (Henry et al., 1999) . Conjugation of two cholesteryl residues to PS-ODNS decreases their accumulation in kidneys approximately 50-fold and is consequently expected to substantially reduce side effects. It was shown previously that conjugation of PS-ODNs with a single cholesterol already substantially increases hepatic uptake and reduces extrahepatic uptake (Crooke et al., 1996; Bijsterbosch et al., 2000) . However, conjugation of a second cholesterol results in an almost exclusive targeting to the liver, spleen, and bone marrow. Furthermore, bis-cholesteryl-conjugated PS-ODN is eliminated more rapidly from the circulation than mono-cholesteryl-conjugated PS-ODN, which reduces the risk of side effects in the circulation, such as complement activation and impaired coagulation (Henry et al., 1999) . For extrahepatic targets, such as ICAM-1 in Crohn's disease or nonhepatic transplants (Stepkowski et al., 1994 (Stepkowski et al., , 1998 Bennett et al., 1997; Yacyshyn et al., 1998) , the benefits of bischolesterol modification are questionable. Several in vitro studies with extrahepatic cells demonstrated a higher antisense activity of cholesteryl-conjugated PS-ODNs, compared with nonconjugated PS-ODNs (Alahari et al., 1996; Epa et al., 1998) . However, the present data indicate that in vivo the bis-cholesteryl-conjugated PS-ODNs are hardly taken up by extrahepatic tissues.
In conclusion, we show in this study that attachment of two cholesterol residues to a PS-ODN results in an almost complete hepatic uptake of the oligonucleotide when injected in the rat. The highest concentrations of the oligonucleotide were found in Kupffer cells and endothelial cells. In addition, we established the predominant role of scavenger receptors in the hepatic uptake. We further show that the bis-cholesterol conjugation affects the interaction with plasma proteins, which may explain its biological fate. The high and selective liver accumulation of the bis-cholesteryl-conjugated PS-ODNs is expected to result in higher in vivo efficacy against hepatic targets. Furthermore, the efficacy of bischolesteryl-conjugated PS-ODNs may improve by other mechanisms, such as more favorable intracellular trafficking.
